niraparib abiraterone acetate

Details

Generic Name:
niraparib abiraterone acetate
Project Status:
Pending
Therapeutic Area:
Metastatic castration-resistant prostate cancer (mCRPC)
Manufacturer:
Janssen Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0326-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the first-line treatment of adult patients with prostate cancer who have progressed to metastatic castration resistant prostate cancer (mCRPC), are asymptomatic/mildly symptomatic, and are positive for deleterious or suspected deleterious BRCA mutation (germline and/or somatic).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For the first-line treatment of adult patients with prostate cancer who have progressed to metastatic castration resistant prostate cancer (mCRPC), are asymptomatic/mildly symptomatic, and are positive for deleterious or suspected deleterious BRCA mutation (germline and/or somatic).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.